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ABSTRACT
Question
What is the efficacy of pharmacologic and non-phar-
macologic treatments for major depression and other
depressive disorders in cancer populations?
Perspectives
Depression occurs at an increased rate in medically
ill populations, including patients with cancer. In the
general population, depression has been shown to be
responsive to structured forms of psychotherapy and
to pharmacologic interventions. The Supportive Care
Guidelines Group conducted a systematic review of
the evidence for the effectiveness of those therapies
in patients with depression and cancer and developed
the present clinical practice guideline based on that
review and on expert consensus.
Outcomes
Outcomes of interest included symptomatic response
to treatment, discontinuation rate of treatment, ad-
verse effects, and quality of life.
Methodology
Clinical recommendations were developed by the
Supportive Care Guidelines Group based on a sys-
tematic review of the published literature through
June 2005, feedback obtained from Ontario health
care providers on the draft recommendations,
the Report Approval Panel (RAP) of Cancer Care
Ontario’s Program in Evidence-Based Care, and ex-
pert consensus.
Results
The systematic review of the literature included
eleven trials (seven of pharmacologic agents and four
of non-pharmacologic interventions). Feedback re-
ceived from 44 responding health care providers and
the RAP on the draft recommendations was addressed
and documented in the guideline.
Among providers, 82% agreed with the draft rec-
ommendations as stated, 68% agreed that the report
should be approved as a practice guideline, and 73%
indicated that they would be likely to use the guide-
line in their own practice.
Practice Guideline
These recommendations apply to adult cancer pa-
tients with a diagnosis of major depression or other
non-bipolar depressive disorders. They do not ad-
dress the treatment of non-syndromal depressive
symptoms, for which specific antidepressant treat-
ment is not usually indicated. The guideline is in-
tended both for oncology health professionals and
for mental health professionals engaged in the
treatment of cancer patients. Expert consensus was
central to the development of the guideline rec-
ommendations because of limited evidence in can-
cer patients.
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Recommendations
Treatment of pain and other reversible physical symp-
toms should be instituted before or with initiation of
specific antidepressant treatment.
Antidepressant medications should be considered
for the treatment of moderate-to-severe major depres-
sion in cancer patients. Current evidence does not
support the relative superiority of one pharmacologic
treatment over another, nor the superiority of phar-
macologic treatment over psychosocial interventions.
The choice of an antidepressant should be informed
by individual medication and patient factors: the side
effect profiles of the medication, tolerability of treat-
ment (including the potential for interaction with other
current medications), response to prior treatment, and
patient preference.
Cancer patients diagnosed with major depression
may benefit from a combined modality approach that
includes both psychosocial and pharmacologic inter-
ventions. Psychosocial treatment approaches that may
be of value include those that provide information
and support and those that address any combination
of emotional, cognitive, and behavioural factors.
Qualifying Statements
Referral to a mental health specialist is appropriate
when the diagnosis of depression is unclear, when
the syndrome is severe, when patients do not respond
to treatment, or when other complicating factors that
may affect the choice of treatment are present.
Although care has been taken in the preparation
of the information contained in this guideline, any
person seeking to apply or to consult the guideline is
expected to use independent medical judgment in the
context of individual clinical circumstances or to seek
out the supervision of a qualified clinician.
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1. QUESTION
What is the efficacy of pharmacologic and non-phar-
macologic treatments for major depression and other
depressive disorders in cancer populations?
Outcomes of interest included symptomatic re-
sponse to treatment, discontinuation rate of treatment,
adverse effects, and quality of life.
2. CHOICE OF TOPIC AND RATIONALE
Major depression occurs in 14%–16% of cancer or
palliative care patients 1,2, a rate approximately twice
to four times that found in the general population 3.
Individuals with serious medical conditions, includ-
ing cancer, are at increased risk for persistent depres-
sive symptoms and disorders, which are associated
with significant disability 4–7. The diagnosis of major
depression may be partially confounded by symp-
toms related to the physical effects of cancer and by
“realistic” feelings of sadness, although evidence
suggests that a valid diagnosis can nevertheless be
made in this context 8.
Depressive disorders in the general population
have been shown to be highly responsive to struc-
tured forms of psychotherapy and to pharmacologic
interventions 9–11. Some studies have shown that the
combination of pharmacotherapy and psychotherapy
is more effective in the treatment of chronic and more
severe forms of depression than is either modality
alone 10,12.
Guidelines for the treatment of major depression
have been published by a variety of organizations,
including the National Institute for Clinical Excel-
lence 13, the American Psychiatric Association 14, and
the Canadian Psychiatric Association 15. Much of the
associated evidence and the guideline recommenda-
tions may be assumed to be applicable to cancer pa-
tients; however, certain factors complicate the
treatment of depressive disorders in that population,
including diagnostic overlap of the symptoms of de-
pression with those of cancer and higher rates of side
effects related to medication and treatment with-
drawal 8. Treatment evaluation may also be complex
because of comorbid factors that contribute to de-
pression in medical populations and that require prior
or simultaneous treatment. For example, cancer pain
is associated with the development and exacerbation
of psychological distress, including depression 16–19
and hopelessness 20. The assessment and treatment
of pain may be an essential step when pain and mood
disturbance coexist 21.
Research on the effectiveness and tolerability of
antidepressant treatment in cancer patients with de-
pressive disorders is relevant because of the poten-
tial for depression in this population to be associated
with various drug–drug interactions and because of
the potential effect of cancer on treatment side ef-
fects, continuation rates, and outcomes. The Support-
ive Care Guidelines Group (SCGG) therefore conducted
a systematic review of the evidence on the efficacy
of pharmacologic and non-pharmacologic treatments
for major depression and other depressive disorders
in cancer populations, and developed the present clini-
cal practice guideline based on that review and on
expert consensus.
3. METHODS
3.1 Development of the Systematic Review
The SCGG of Cancer Care Ontario’s Program in Evi-
dence-Based Care (PEBC) comprises medical, radia-
tion, and surgical oncologists; psychiatrists; palliative
care physicians; nurses; radiation therapists; meth-
odologists; administrators; a psychologist; and anRODIN et al.
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anesthetist. The PEBC is sponsored by, but is editori-
ally independent of, Cancer Care Ontario and the
Ontario Ministry of Health and Long-Term Care.
In 2005, a working group of the SCGG conducted
a systematic review of the evidence for pharmaco-
logic and non-pharmacologic treatment of depression
in cancer patients. That review included literature
published through June 2005, and the sources
searched included MEDLINE, EMBASE, CINAHL, PsycINFO,
and the Cochrane Library. Based on predefined cri-
teria, comparative studies of treatments for depres-
sion in cancer patients were selected for review by
two SCGG members. The studies were evaluated and
summarized by the working group, and the completed
systematic review was approved by the full SCGG 22.
3.2 Development of the Clinical Practice Guideline
Based on the completed systematic review 22 and ex-
pert consensus, the working group used the methods
of the practice guidelines development cycle 23 to draft
a clinical practice guideline. The full SCGG reviewed
and approved the draft guideline. The draft guideline
and systematic review, together with a structured sur-
vey, were distributed for external feedback to 236
health care providers in Ontario, including 101 psy-
chiatrists, 40 medical oncologists, 41 pharmacists,
39 nurses, and 15 palliative care physicians. The sur-
vey consisted of items evaluating the methods, results,
and discussion used to inform the draft guideline rec-
ommendations, and questions concerning whether the
recommendations should be approved as a practice
guideline. Written comments were also invited. The
survey was mailed to the recipients over a period of
4 months (September through December 2005), with
follow-up reminders sent at 2 weeks (postcard) and
4 weeks (complete package mailed again). The work-
ing group reviewed the provider feedback, docu-
mented the results of the feedback in the final practice
guideline, and revised the guideline accordingly.
In addition, the revised guideline and systematic
review were reviewed and approved by the full SCGG
and the PEBC Report Approval Panel (RAP) in October
2006. The RAP consists of two members, including
an oncologist, with expertise in clinical and
methodologic issues. The completed guideline is in-
tended to promote evidence-based practice and will
be posted on the Cancer Care Ontario Web site
(www.cancercare.on.ca), together with other guide-
lines produced by the PEBC. The guideline will un-
dergo periodic review and will be revised as new
evidence becomes available.
4. RESULTS
4.1 Systematic Review of the Evidence
Evidence for the effectiveness of pharmacologic and
non-pharmacologic interventions in the treatment of
cancer patients with depressive disorders was limited.
One systematic review 24, seven trials of pharmaco-
logic agents 25–31, and four trials of non-pharmacologic
interventions 32–35 were identified as relevant. Three
of the eleven trials included only patients diagnosed
with major depression through structured diagnostic
interview. The remaining eight trials included patients
with depressive symptoms above a predefined cut-off
score determined using a validated assessment tool.
The treatment period and follow-up was short in the
trials of pharmacologic treatments (10 days to
12 weeks), which limits the conclusions that can be
reached regarding long-term treatment.
The systematic review of twenty-four studies in
cancer patients (six focused on antidepressant agents
and eighteen on psychosocial interventions) found
limited evidence in favour of both treatments 24. How-
ever, few studies in the review focused on patients
diagnosed with a depressive disorder; most were stud-
ies of prevention or included patients with mild de-
pressive symptoms.
Two pharmacologic trials comparing mianserin
to placebo detected a significant benefit with treat-
ment 25,31. In another trial, alprazolam was found to
be superior to progressive muscle relaxation in re-
ducing depressive symptoms 27. Four of the pharma-
cologic trials found no significant difference between
groups on a measure of depression 26,28–30. Two of
those trials compared low-dose fluoxetine to pla-
cebo 26,30, one compared fluoxetine to desipramine 28,
and one compared paroxetine to amitriptyline 29. In
the latter two studies, significant pre–post treatment
effects occurred for both active comparators, but the
significance of these findings in the absence of pla-
cebo comparators is limited. Only one of the phar-
macologic trials assessed outcome based on remission
of depressive symptoms to within the normal range
as opposed to response, which is a less stringent
outcome.
Two of the four trials that assessed non-pharma-
cologic therapies for the management of depression
found a significant difference between treatment
groups. One trial found a benefit in using a multi-
component nurse-delivered intervention 35, with a re-
duction in the number of patients diagnosed with
major depression. The other positive trial found the
use of an orientation program to be beneficial in re-
ducing depressive symptoms 34. In both trials, the
control group received usual care. Neither group psy-
chotherapy nor adjuvant psychological therapy (cog-
nitive behavioural therapy) was found to significantly
reduce depressive symptoms in the other two non-
pharmacologic trials 32,33.
4.2 Practitioner Feedback
The draft clinical practice guideline and systematic
review were circulated to 236 health care providers
in Ontario for review and feedback. From among thePRACTICE GUIDELINE SERIES
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236 surveys mailed, 75 responses were received (32%
response rate). Of the respondents, 44 individu-
als—including 13 medical oncologists, 11 nurses,
10 psychiatrists, 7 palliative care physicians, and
3 pharmacists—indicated that the report was relevant
to their clinical practice, and they completed the sur-
vey. Table I shows key results of the external review
survey, summarized by respondent discipline.
Among all respondents, 36 (82%) agreed with
the draft recommendations as stated (7% neither
agreed nor disagreed); 30 (68%) agreed that the re-
port should be approved as a practice guideline (14%
neither agreed nor disagreed); and 32 (73%) indicated
that they would be likely to use the guideline in their
own practice (18% were unsure). Written comments
related to the content of the report were provided by
TABLE I Responses to eight items on the external review survey
Item Responders [n (%)] a
Strongly agree Neither agree Strongly disagree
or agree nor disagree or disagree
The rationale for developing a guideline, as stated in the Psychiatrists 9 (90) 1 (10) 0
Introduction section of the Systematic Review, is clear. Medical oncologists b1 11 (85) 1 (8) 0
Nurses 9 (82) 0 2 (18)
Palliative care physicians 7 (100) 0 0
Pharmacists 3 (100) 0 0
There is a need for a guideline on this topic. Psychiatrists 10 (100) 0 0
Medical oncologists b1 9 (69) 3 (23) 0
Nurses 9 (82) 0 2 (18)
Palliative care physicians 7 (100) 0 0
Pharmacists 3 (100) 0 0
The literature search is relevant and complete. Psychiatrists b1 7 (70) 2 (20) 0
Medical oncologists b1 10 (77) 2 (15) 0
Nurses b1 6 (55) 2 (18) 2 (18)
Palliative care physicians 3 (43) 4 (57) 0
Pharmacists 1 (33) 1 (33) 1 (33)
The results of the trials described in the Systematic Psychiatrists 8 (80) 1 (10) 1 (10)
Review are interpreted according to my Medical oncologists b1 7 (54) 5 (38) 0
understanding of the data. Nurses 8 (73) 1 (9) 2 (18)
Palliative care physicians b2 4 (57) 1 (14) 0
Pharmacists 3 (100) 0 0
The draft recommendations in the Clinical Practice Psychiatrists 10 (100) 0 0
Guideline are clear. Medical oncologists b1 12 (92) 0 0
Nurses 9 (82) 0 2 (18)
Palliative care physicians b1 4 (57) 0 2 (29)
Pharmacists 3 (100) 0 0
I agree with the draft recommendations as stated. Psychiatrists 9 (90) 0 1 (10)
Medical oncologists b1 11 (85) 1 (8) 0
Nurses 8 (73) 2 (18) 1 (9)
Palliative care physicians b1 5 (71) 0 1 (14)
Pharmacists 3 (100) 0 0
This report should be approved as a practice guideline. Psychiatrists 7 (70) 2 (20) 1 (10)
Medical oncologists b1 11 (85) 1 (8) 0
Nurses b1 6 (55) 2 (18) 2 (18)
Palliative care physicians 4 (57) 1 (14) 2 (28)
Pharmacists 2 (67) 0 1 (33)
Very likely Unsure Not at all likely
or likely or unlikely
If this report were to become a practice guideline, how Psychiatrists 6 (60) 3 (30) 1 (10)
likely would you be to make use of it in your Medical oncologists b1 10 (77) 2 (15) 0
own practice? Nurses b1 8 (73) 2 (18) 0
Palliative care physicians 5 (71) 1 (14) 1 (14)
Pharmacists 3 (100) 0 0
a Percentages may not add to 100% because of rounding.
bx Some responders (n = x) did not answer this question.RODIN et al.
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21 respondents (48%). Several respondents thought
that the systematic review was well done and that the
guideline was an important initiative. The main points
contained in the remaining written comments are sum-
marized in the subsection that follows.
4.2.1 Comments on the Recommendations
Based on the expert consensus of the group, the draft
guideline included recommendations for specific
pharmacologic agents. Some respondents commented
on the lack of evidence for most of the agents, noting
the limitation of having only two psychiatrists within
the group as a source of consensus. The sub-recom-
mendation on “treatment of pain” was considered too
rigid by some respondents; they indicated that con-
current use of pain management and antidepressant
medications is sometimes appropriate. One respon-
dent suggested that tricyclic antidepressants could be
mentioned within the recommendations, if only to
discourage their use in major depression unless as an
adjuvant agent in analgesia. It was also suggested
that the guideline could include discussions concern-
ing when to defer to a specialist (psychologist, social
worker, psychiatrist) and the issues involved in the
collaborative care of cancer patients.
4.2.2 Comments on the Evidence
Survey respondents commented on a number of stud-
ies that they felt were of interest or that should be
included in the report, and they mentioned a need for
clearer identification of the evidence for treatment of
depression in other medically ill populations.
4.2.3 Other Comments
A number of respondents commented on the use of
screening for depression. One felt that the review
should include stronger emphasis on the need for
systematic screening, although such screening may
require reorganization of resources. One suggested
that a recommended screening tool for depression in
cancer patients would be useful, and one indicated
that the use of screening tools is of limited benefit in
patients with depersonalization, who benefit little
from the use of antidepressants. Two respondents
commented on the need for family doctors,
oncologists, and other specialists to become involved
in the assessment and treatment of depression in can-
cer patients so that treatment is actually offered where
indicated. One respondent remarked that support from
psychiatrists would be needed for such an effort, and
one suggested that support for the families and
caregivers of patients should also be considered, be-
cause they are at higher risk for depression.
4.3 Guideline Group and PEBC Report Approval
Panel
The final guideline was reviewed and approved by
the RAP and the full SCGG in October 2006. Key is-
sues raised by the RAP included a need for clarifica-
tion on the intended provider audience for the report
and consideration of the presentation of the infor-
mation for the specific audience. Also, given the lim-
ited evidence for treatment options in cancer patients,
they requested further discussion of the evidence for
treatment effectiveness in non-cancer populations.
The latter point was also raised by participants dur-
ing the external review process. Similarly, the full
SCGG commented on the need for greater emphasis
in the guideline on the mixed evidence regarding the
impact of screening for depression on patient out-
comes, an issue that was also raised during external
review.
5. DISCUSSION
During initial discussions on the development of a
guideline for the treatment of depressive disorders
in cancer patients, the SCGG members raised three
questions:
• First, how valid and reliable is the diagnosis of
depressive disorder in cancer patients, and what
is the prevalence and course of this condition in
the population with cancer?
• To what extent do systematic reviews, meta-
analyses, and randomized controlled trials con-
firm the efficacy of antidepressant treatments in
the population with cancer?
• Do guidelines for the treatment of depressive dis-
orders in cancer patients and in other populations
already exist?
These questions directed the discussion toward
development of a guideline, with the group deciding
to focus on the treatment of depression. Screening
and diagnosis of depression in cancer patients would
be a topic for future consideration.
The SCGG found that the evidence suggests that a
valid and reliable diagnosis of major depression can
be made in the cancer population despite the overlap
of symptoms of depression with those of cancer and
its treatment. Depressive symptoms have been shown
to persist and to be associated with significant mor-
bidity in medically ill populations. Because milder
depressive symptoms are a common non-specific
manifestation of distress in cancer patients, a group
decision was made to focus on the syndrome of major
depression, for which specific interventions have been
developed.
The “gold standard” for the diagnosis of major
depression is a structured diagnostic interview; how-
ever, because of limited evidence in the population
under consideration, the guideline was subsequently
expanded to include studies of patients with depres-
sive symptoms above a predefined cut-off point on a
validated depression assessment scale. In addition,
given the available evidence, the group decided toPRACTICE GUIDELINE SERIES
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present the evidence in two distinct categories: phar-
macologic trials, and trials of non-pharmacologic
interventions.
Following review of the draft guideline by On-
tario health care providers, the full SCGG, and the RAP,
a number of revisions were incorporated into the
guideline. The working group acknowledged the limi-
tations of the current evidence, considered the dis-
parity between available research evidence and
current practice, and discussed the value of provid-
ing guidance for clinicians on the use of specific phar-
macologic agents in the absence of evidence.
Although opinions varied, the group agreed that rec-
ommendations for specific antidepressants in the ab-
sence of evidence would not be provided within the
current guideline. Instead, recommendations on fu-
ture research to evaluate specific antidepressants were
provided.
The working group discussed referral of patients
to a specialist (psychologist, social worker, psychia-
trist) and the issues involved in the collaborative care
of patients. They emphasized the need for all health
care providers to be alert to signs and symptoms of
depression in cancer patients, and they agreed that
referral to a mental health specialist is most appro-
priate when the diagnosis of depression is unclear,
when the syndrome is severe, when patients do not
respond to treatment, or when other complicating
factors that may affect the choice of treatment are
present. A qualifying statement to this effect was
added to the guideline.
With regard to the recommendation on treatment
of pain, the group felt that the current recommenda-
tion did not preclude concomitant pain management
and depression treatment and did not require revi-
sion. Similarly, at the present time, they chose not to
add a recommendation explicitly discouraging the use
of tricyclic antidepressants, because although newer
classes of antidepressants have fewer side effects than
tricyclics, the new agents have not been shown to be
more effective than tricyclics.
The working group considered the additional ref-
erences identified by the external reviewers and, al-
though of interest, none of those studies met the
predefined inclusion criteria for the systematic review
of the evidence. However, the need for clearer iden-
tification of evidence for treatment of depression in
other medically ill populations was raised by a num-
ber of external reviewers and by the RAP. As a result,
discussion of this evidence and its relevance to the
treatment of depression in cancer patients was ex-
panded within the systematic review, although this
change did not require a change in the guideline
recommendations.
Another key issue that was raised by external
reviewers and by some SCGG members was the evi-
dence related to screening for depression. Evidence
from the general population and from patients with
other medical conditions suggests that screening for
depression may result in increased recognition of
depression; however, evidence for a positive impact
of such screening on the management of depression
or on outcome has been mixed 36,37. Because a sys-
tematic review of the evidence on screening was
not conducted for this guideline, no recommenda-
tions could be made on the need for systematic
screening programs at this time. Instead, when de-
pression is detected, the guideline emphasizes that
appropriate treatment, follow-up, and referral should
be undertaken as necessary. The evaluation of de-
pression screening tools (suggested by one external
reviewer) is beyond the scope of the current guide-
line and will be considered for future report
development.
The current guideline is intended both for on-
cology health professionals and for mental health
professionals engaged in the treatment of cancer pa-
tients, and in response to the RAP feedback, a section
on the target provider population was added to the
guideline. Although mental health professionals may
have more expertise in the use of screening tools for
depression, it is not clear that the method of detec-
tion or presentation of depression affects treatment
outcomes, and therefore this guideline is also con-
sidered appropriate for oncology health profession-
als. The need for a range of health care professionals
to become involved in the assessment and treatment
of depression in cancer patients is acknowledged.
The hope is that this report will provide guidance
regarding treatment options. The importance of the
broader issue of assessment and treatment of fami-
lies and caregivers of cancer patients is recognized;
however, broader guidelines for treatment of depres-
sion in non-medical populations would also apply
in that population.
6. PRACTICE GUIDELINE
Clear evidence derived from randomized controlled
trials in cancer patients that could be used to inform
conclusions is absent. The recommendations that fol-
low therefore reflect the expert consensus of the SCGG
members, informed by the evidence reviewed and by
the feedback received from Ontario health care pro-
viders and the PEBC RAP.
6.1 Target Patient Population
These recommendations apply to adult cancer patients
with a diagnosis of major depression or other non-
bipolar depressive disorders. They do not address the
treatment of non-syndromal depressive symptoms,
for which specific antidepressant treatment is not
usually indicated. Such symptoms are frequent as
non-specific manifestations of distress or in associa-
tion with pain or other suffering. For the purposes of
this guideline, conclusions are based on evidence
from studies in two categories of patients:RODIN et al.
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• Patients diagnosed with major depression by a
structured diagnostic interview. This method is
the “gold standard” for a diagnosis of a depres-
sive disorder.
• Patients with depressive symptoms scoring more
than 14 on the first 17 items of the Hamilton
Depression Rating Scale, 8 or higher on the Hos-
pital Anxiety and Depression Scale, or above
the equivalent cut-off on another validated as-
sessment scale, realizing the these measures
were developed to assess symptoms. They are
used for screening, but they are less stringent
methods for diagnosing depressive disorders
because they may be associated with false posi-
tives and false negatives. Some (but not all) of
these patients may have been suffering from
major depression, dysthymic disorder, adjust-
ment disorder with depressed mood, or minor
depression.
6.2 Target Provider Population
The guideline is intended both for oncology health
professionals and for mental health professionals
engaged in the treatment of cancer patients. Referral
to a mental health specialist may be valuable for can-
cer patients diagnosed with major depression, but
such a referral may not always be feasible. The rate
of detection of depressive disorders in this and other
populations is increased by the use of screening mea-
sures, but there is no evidence that the nature of the
disorders or their response to treatment varies by the
method of detection or presentation.
6.3 Recommendations
Treatment of pain and other reversible physical
symptoms should be instituted before or with initia-
tion of specific antidepressant treatment.
Antidepressant medications should be consid-
ered for the treatment of moderate-to-severe major
depression in cancer patients. Current evidence does
not support the relative superiority of one pharma-
cologic treatment over another, nor the superiority
of pharmacologic treatment over psychosocial inter-
ventions. The choice of an antidepressant should be
informed by individual medication and patient fac-
tors: the side effect profiles of the medication, toler-
ability of treatment (including the potential for
interaction with other current medications), response
to prior treatment, and patient preference.
Cancer patients diagnosed with major depression
may benefit from a combined modality approach that
includes both psychosocial and pharmacologic in-
terventions. Psychosocial treatment approaches that
may be of value include those that provide informa-
tion and support and those that address any combi-
nation of emotional, cognitive, and behavioural
factors.
6.4 Qualifying Statements
Referral to a mental health specialist is appropriate
when the diagnosis of depression is unclear, when
the syndrome is severe, when patients do not respond
to treatment, or when other complicating factors that
may affect the choice of treatment are present.
Although care has been taken in the preparation
of the information contained in this guideline, any
person seeking to apply or to consult the guideline is
expected to use independent medical judgment in the
context of individual clinical circumstances or to seek
out the supervision of a qualified clinician.
7. FUTURE RESEARCH
Large multicentre studies of patients with histologi-
cally similar cancers are required to evaluate the ef-
ficacy of antidepressant interventions, including the
relative benefit of psychological versus pharmaco-
logic interventions in specific cancers, in which medi-
cation side effect profiles, physical symptoms and
psychosocial problems, and the efficacy of specific
antidepressant medications may vary. Indications for
specific medications that deserve further investiga-
tion include the potential value of mirtazapine in the
treatment of mood disorders accompanied by nau-
sea, weight loss, insomnia, or anxiety; the use of dual-
action antidepressants such as mirtazapine,
venlafaxine, and duloxetine in the treatment of co-
morbid pain and depression; and the use of sustained
release bupropion for cancer patients with significant
symptoms of depression and fatigue.
Further studies are needed to evaluate the rela-
tive effectiveness and tolerability of newer antide-
pressant treatments and the use of combination
strategies for treatment-resistant depressive disorders.
The latter potentially include the use of two antide-
pressant medications used in combination and the use
of antidepressants combined with either lithium or
atypical antipsychotics.
Research is needed to identify strategies to im-
prove the rates of detection and treatment comple-
tion in cancer patients with depressive disorders.
8. PRACTICE GUIDELINE DATE
The present clinical practice guideline report is based
on work completed in October 2006. All approved
PEBC reports are updated periodically and posted on
the Cancer Care Ontario Web site (www.cancercare.
on.ca/index_practiceGuidelines.htm).
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